INTRODUCTION
============

First described by Allfrey and co-workers some 60 years ago as a possible means of regulating RNA synthesis, reversible lysine acetylation (Ac-Lys) is well conserved across organisms, having been described in prokaryotes and eukaryotes ([@b9-molce-38-4-297]; [@b17-molce-38-4-297]; [@b39-molce-38-4-297]). Along with other post-translational modifications (PTMs; e.g., phosphorylation, methylation, ubiquitylation), acetylation is one mechanism by which the cell refines and enacts a complex control strategy in response to varying cellular and physiological processes ([@b9-molce-38-4-297]; [@b39-molce-38-4-297]). Indeed, regulatory enzymes that control acetylation have been implicated in cancer, cardiovascular disease, neurodegeneration, and type 2 diabetes (T2D) ([@b9-molce-38-4-297]; [@b39-molce-38-4-297]). Lysine acetylation involves the transfer of an acetyl group from acetyl-CoA to the ɛ-amino group in the target lysine. Acetyltransferases (KATs) and deacetylases (DACs) regulate this enzymatic process. The twenty identified KATs are split into three major families: MOZ YBF2/SAS3 and TIP60 protein 1 (MYST), general control of amino acid synthesis protein 5 \[GCN5\] related N-acetyltransferase (GNAT), and CREB binding protein/E1A binding protein p300 (CBP/p300) ([@b4-molce-38-4-297]; [@b9-molce-38-4-297]; [@b39-molce-38-4-297]). The eighteen DACs are categorized in two major families; Zn^2+^-dependent and NAD^+^-dependent ([@b9-molce-38-4-297]; [@b39-molce-38-4-297]).

Despite the discovery of acetylation 60 years ago and identification of the first DACs and KATs some 20 years ago, only within the last decade has the extent to which acetylation influences cellular function begun to be appreciated ([@b9-molce-38-4-297]; [@b26-molce-38-4-297]; [@b39-molce-38-4-297]). A driving force behind this transition has been mass spectrometry (MS)-based proteomic approaches, and the advent of 'acetylomics'. A detailed discussion on MS studies of acetylation and potential relevant physiology, including in skeletal muscle, can be found elsewhere ([@b9-molce-38-4-297]; [@b26-molce-38-4-297]; [@b39-molce-38-4-297]). For example, a recent study using high-resolution MS in 16 rat tissues mapped 15,474 acetyl specific modification sites on 4,541 proteins, revealing the acetylome to be at least comparable in size to the phosphorylome ([@b22-molce-38-4-297]). Of particular interest to this Mini Review, pathway enrichment analysis in human and rat skeletal muscle identified numerous acetylated proteins related to the insulin signaling pathway and glucose metabolism ([@b22-molce-38-4-297]). And because cellular NAD^+^ and acetyl CoA concentrations change in response to perturbations in nutrient and metabolic flux, which in turn alters the activity of KATs and NAD^+^-dependent DACs, reversible acetylation provides a natural link between nutrient availability and regulation of insulin action. Indeed, brief caloric restriction (CR) in humans and rodents potently enhances skeletal muscle insulin sensitivity ([@b16-molce-38-4-297]; [@b40-molce-38-4-297]), with clinical studies demonstrating that the majority of the improvement in insulin action during weight loss, or after gastric bypass, occurs during the first week of intervention, and before substantial weight loss occurs ([@b2-molce-38-4-297]; [@b14-molce-38-4-297]; [@b16-molce-38-4-297]). The opposite is also true, as short-term hypercaloric feeding rapidly induces skeletal muscle insulin resistance ([@b40-molce-38-4-297]). Conceptually, this presents an intriguing physiological model, such that changes in food intake are rapidly "translated" into a metabolic adaptation (namely insulin action) at the level of skeletal muscle. An obvious follow up question being, how is a nutritional cue, at the level of food intake, "sensed" and translated into altered insulin sensitivity at the level of skeletal muscle? Accordingly, the primary focus of this review is on the potential contribution of acetylation to regulation of insulin signaling and glucose metabolism in skeletal muscle.

THE BASICS OF INSULIN SIGNALING
===============================

Canonical insulin signaling is characterized by the step-wise progression of kinase phosphorylation, with select phosphatases negatively regulating these kinases. Our focus here is on insulin signaling for glucose transport and metabolism through Akt-PI3K (phosphoinositide \[PI\]-3 kinase), which we discuss briefly below. A detailed perspective on the nuances of canonical and non-canonical insulin signaling, can be found elsewhere ([@b10-molce-38-4-297]; [@b20-molce-38-4-297]; [@b38-molce-38-4-297]).

Regarding insulin signaling for glucose transport, insulin binds the extracellular pocket of the transmembrane insulin receptor (IR), leading to intrinsic autophosphorylation on its cytoplasmic domain ([@b10-molce-38-4-297]; [@b20-molce-38-4-297]; [@b38-molce-38-4-297]). The phosphorylated cytoplasmic domain of IR recruits and then phosphorylates its downstream target, IR substrate (IRS) 1 and/or 2 ([@b10-molce-38-4-297]; [@b20-molce-38-4-297]; [@b38-molce-38-4-297]). Upon IRS phosphorylation, the PI3K p85/p110 heterodimer is recruited and binds IRS at the plasma membrane, where it phosphorylates the plasma membrane lipid PI-(4,5)-bisphosphate (PIP~2~), producing PI-(3,4,5)-bisphosphate (PIP~3~). PIP~3~ binds 3-PI-dependent protein kinase-1 (PDK1) and Akt (also known as protein kinase B), allowing PDK1 to phosphorylate Akt at Thr^308^. Subsequently, Akt is phosphorylated at Ser^473^ by mammalian target of rapamycin complex 2 (mTORC2), with phosphorylation on these two sites being necessary for full Akt activation ([@b10-molce-38-4-297]; [@b20-molce-38-4-297]; [@b38-molce-38-4-297]). Activated Akt phosphorylates numerous downstream substrates leading to physiological changes in glucose, lipid, and protein metabolism within the skeletal muscle ([@b20-molce-38-4-297]; [@b38-molce-38-4-297]). Regarding glucose metabolism, Akt-substrate of 160 kDa (AS160) and glycogen synthase kinase-3β (GSK3β), are two key Akt substrates that facilitate glucose uptake and storage, respectively ([@b10-molce-38-4-297]; [@b20-molce-38-4-297]; [@b38-molce-38-4-297]). Specifically, Akt phosphorylation of AS160 relieves its inhibitory effect on GLUT4 allowing its translocation to the plasma membrane, which facilitates glucose diffusion into the cell ([@b34-molce-38-4-297]). GSK3β phosphorylation relieves its inhibition of glycogen synthase (GS), thereby promoting glycogenesis ([@b10-molce-38-4-297]).

EFFECTS OF ACETYLATION ON INSULIN SIGNALING
===========================================

Below we take a step-wise look at the insulin signaling pathway, discuss known and proposed effects of acetylation on insulin signaling, and postulate the implications for this on insulin-stimulated glucose transport. A list of known acetylation sites in insulin signaling proteins is provided in [Table 1](#t1-molce-38-4-297){ref-type="table"}.

IR and insulin-like growth factor 1 receptor (IGF1R)
----------------------------------------------------

Significant functional and structural similarities exist between IR and IGF1R ([@b20-molce-38-4-297]; [@b38-molce-38-4-297]). In recent global acetylation analyses, Lys^1088^ in IGF1R was acetylated in a human myeloid leukemia cell line, MV4-11 ([@b8-molce-38-4-297]). Interestingly, Lys^1088^ is in the kinase domain of IGFR1, a region that is highly conserved between IGF1R and IR, suggesting that this site may be important for regulating the function of these proteins ([@b8-molce-38-4-297]; [@b28-molce-38-4-297]). Supporting this, in C~2~C~12~ myotubes (which is an immortalized muscle-like cell line) inhibition of histone deacetylase 2 (HDAC2) activity increased pIR^Tyr1146^, pAkt^Ser473^, glucose uptake and glycogen synthesis ([@b35-molce-38-4-297]), although whether this was due to changes in acetylation of IR was not assessed. Thus, whether acetylation affects the binding of insulin to the receptor or the activity and downstream transduction of IR/IGF1 signaling remains to be determined. It is important to note that Lys^1088^ was not identified in human skeletal muscle ([@b8-molce-38-4-297]), which perhaps questions the relevance of this modification to IR or IGF1R function in skeletal muscle.

IRS proteins
------------

Three Ac-Lys sites on IRS1 and four on IRS2 have been identified ([Table 1](#t1-molce-38-4-297){ref-type="table"}) ([@b44-molce-38-4-297]; [@b46-molce-38-4-297]). Interestingly, two Ac-Lys sites (Lys^52^ and Lys^61^) in IRS1 lie within the pleckstrin homology (PH) domain, which is required for recognizing and binding PIP~3~. This suggests that acetylation may affect how IRS1 recognizes phosphorylated domains in other proteins, and therefore insulin signaling through IRS1. In support of this, in co-immunopreciptiation experiments in liver lysates from Balb/cJJ and *ob/ob* mice, HDAC2 pulled down with IRS1, although this did not occur in lysates from C57BL/6J mice ([@b15-molce-38-4-297]). Further supporting a role for acetylation in regulating IRS1 function, treatment of the MCF-7 breast cancer cell line (which has high IRS1 expression) with the DAC inhibitor, trichostatin A (TSA), increased both IRS1 acetylation and insulin-stimulated IRS1 tyrosine phosphorylation (pIRS1^Tyr^) ([@b15-molce-38-4-297]). In contrast, phorbol myristic acid (PMA), a protein kinase C (PKC) activator, increased HDAC2-IRS1 interaction and reduced insulin-stimulated pIRS1^Tyr^ ([@b15-molce-38-4-297]). Lastly, in H4IIE cells, SIRT1 inhibitors decreased IRS2 phosphorylation, impaired the pAkt^Ser473^ insulin signaling response, and subsequent mutation of putative Lys^118/289/292/412^ residues in IRS2 reduced insulin-stimulated pIRS2^Tyr^ ([@b44-molce-38-4-297]). Additionally, SIRT2 has been shown up regulated in insulin resistant C~2~C~12~ myotubes, however its effect on IRS1/2 acetylation state was not directly shown ([@b1-molce-38-4-297]). Putting these studies together, it appears that acetylation of IRS1 and IRS2 has opposing effects; IRS1 acetylation promotes its tyrosine phosphorylation, whilst acetylation of IRS2 inhibits it. The utility of these opposing effects are not readily apparent, it presents an interesting paradigm in which two insulin receptor substrates require differential modulation of their acetylation marks to affect downstream changes.

PI3K
----

Class 1A PI3K, a central signaling node for insulin-stimulated glucose transport, is a heterodimeric protein that is composed of a regulatory subunit (p85α, p85β, p50α, or p55α) and a catalytic subunit (p110α or p110β) ([@b38-molce-38-4-297]). MS analysis in non-muscle tissue has identified multiple Ac-Lys residues within the regulatory (p85α and p55α) and catalytic (p110β and p100γ) subunits ([Table 1](#t1-molce-38-4-297){ref-type="table"}). For p85α, acetylation sites have been identified in the C-terminal SH2 and the inter-SH2 (which is between the N- and C-terminal SH2 domains) domains. These regions are important for docking to tyrosine-phosphorylated proteins, such as IRS proteins, and also for binding p110. For p110, there are no reported acetylation sites on p110α, whilst for p110β there are two Ac-Lys sites in close proximity to the p85 binding domain and the PI3K ras-binding domain. However, whether or not these acetylation marks effect heterodimer formation or PI3K function remains to be determined. In addition, to date, in skeletal muscle only the p55α subunit has been identified as having an Ac-Lys ([@b22-molce-38-4-297]), so clearly more detailed work is needed.

PDK1 and Akt acetylation
------------------------

PDK1 and its downstream target, Akt, are serine-theronine kinases that recognize the PI3K generated second messenger, PIP~3~, through their pleckstrin homology (PH) domain. Multiple acetylation sites have been identified in the kinase and PH domain of PDK1 and Akt ([Table 1](#t1-molce-38-4-297){ref-type="table"}). For example, in cardiac myocytes, p300 and p300/CBP-associated factor (PCAF) acetylate lysine residues in the PH domains of Akt (Lys^14^ and Lys^20^) and PDK1 (Lys^495^ and Lys^534^), negatively regulating their interaction with PIP~3~ ([@b36-molce-38-4-297]). Additionally, in MS analysis, Lys^378^ within the kinase domain of Akt2, was acetylated. In contrast, SIRT1-mediated deacetylation of these residues promoted their activation through enhanced binding of Akt and PDK1 to PIP~3~ ([@b36-molce-38-4-297]) Interestingly, in skeletal muscle, there was a decrease in Ac-Akt after insulin stimulation in fasted mice (but not non-fasted mice), and concomitant greater activation of Akt ([@b36-molce-38-4-297]). While effects on insulin-stimulated glucose uptake were not assessed in this study, we ([@b42-molce-38-4-297]; [@b43-molce-38-4-297]) and others ([@b3-molce-38-4-297]) find that overexpression of SIRT1 in skeletal muscle does not enhance Akt activation (as measured by pAkt^Ser473^ and pAkt^Thr308^) or insulin sensitivity. In contrast, SIRT1 is required for the ability of caloric restriction to enhance skeletal muscle insulin action, through a mechanism upstream of PDK1-Akt, at the level of PI3K ([@b32-molce-38-4-297]). Although Ac-Akt was not measured in these studies, overall they do suggest that the contribution of SIRT1 to PDK1-Akt function in skeletal muscle is less definitive than in cardiac tissue.

Interestingly, in non-skeletal muscle cell lines that have normal insulin-regulated Akt activation, SIRT2, but not SIRT1, bound strongly to Akt and appeared to negatively regulate insulin-stimulated Akt activation ([@b29-molce-38-4-297]). Supporting a role for SIRT2 in negatively regulating Akt function, SIRT2 expression is increased in insulin resistant C~2~C~12~ myotubes and pharmacological- or knockdown-based inhibition of SIRT2 increases insulin signaling, Akt phosphorylation, and glucose uptake ([@b1-molce-38-4-297]). While SIRT2 was not specifically shown to deacetylate Akt in these studies, inhibition of SIRT2 in a hepatocellular carcinoma cell line increased Ac-Akt ([@b7-molce-38-4-297]).

Negative regulators of insulin signaling
----------------------------------------

Phosphatase and tensin homolog (PTEN) negatively regulates insulin signaling by dephosphorylating PIP~3~ ([@b37-molce-38-4-297]). Multiple Ac-Lys sites are present in the phosphatase domain of PTEN ([Table 1](#t1-molce-38-4-297){ref-type="table"}), and growth factor stimulation in HEK293 cells suggest that PCAF-mediated acetylation in this domain at Lys^125^ and Lys^128^ inhibits its ability to dephosphorylate PIP~3~ ([@b25-molce-38-4-297]). In addition, PTEN acetylation is increased in SIRT1-deficient embryonic stem cell (ES), suggesting that PCAF and SIRT1 reciprocally regulate PTEN acetylation and PIP~3~ accumulation ([@b6-molce-38-4-297]).

Protein tyrosine phosphotase 1B (PTP1B) negatively regulates insulin signaling by dephosphorylating the IR ([@b18-molce-38-4-297]; [@b30-molce-38-4-297]). Two acetylation sites are present in the phosphatase domain of PTP1B ([Table 1](#t1-molce-38-4-297){ref-type="table"}), although whether these activate or inhibit its function is not known. Lastly, examination of potential acetylation sites in other negative regulators of insulin signaling such as SKIP2, SHIP and TRB3 ([@b20-molce-38-4-297]; [@b38-molce-38-4-297]), reveals that only SHIP2 has a known Ac-Lys site ([Table 1](#t1-molce-38-4-297){ref-type="table"}); its function, however, is not known.

mTORC2
------

mTOR is a serine-threonine kinase that plays a central role in glucose metabolism and insulin signaling ([@b20-molce-38-4-297]; [@b33-molce-38-4-297]; [@b38-molce-38-4-297]). mTORC2, which contains the rapamycin-insensitive complex, Rictor, is required for Ser^473^ phosphorylation and full activation of Akt ([@b20-molce-38-4-297]; [@b38-molce-38-4-297]). Rictor is a scaffolding protein within the mTORC2 complex that is required for proper function of mTORC2 activity, and its response to upstream insulin signaling ([@b31-molce-38-4-297]; [@b33-molce-38-4-297]). Rictor contains a central region (amino acids between 1040--1140) that confers stability to mTORC2 and this region is highly acetylated with nine Ac-Lys residues ([Table 1](#t1-molce-38-4-297){ref-type="table"}); lysine mutants in this region of Rictor exhibit impaired pAkt^Ser473^ ([@b13-molce-38-4-297]). Additionally, in HEK293 cells p300 overexpression or NAD^+^-dependent DAC inhibitors increased acetylation of Rictor, implicating these proteins in the regulation of Rictor and mTORC2 function.

GLUCOSE METABOLISM
==================

In skeletal muscle, a post-prandial increase in circulating insulin normally results in increased glucose uptake into the myocyte, of which approximately one-third enters glycolysis and two-thirds is converted to glycogen ([@b11-molce-38-4-297]). Thus, coordination and matching of insulin-stimulated glucose uptake with this glucose 'disposal' is essential. In line with our discussions above on insulin signaling, recent MS-based analysis have found that essentially all enzymes in glycolysis and glycogen synthesis contain at least one, and in some cases as many as twenty nine, Ac-Lys sites ([Table 2](#t2-molce-38-4-297){ref-type="table"}) ([@b8-molce-38-4-297]; [@b22-molce-38-4-297]; [@b41-molce-38-4-297]). While the precise role of acetylation to the function of these enzymes, especially those that are highly acetylated, remains to be fully elucidated, it is not unreasonable to infer that they likely contribute to their enzymatic activity. We discuss some examples of this below.

Gycolysis
---------

Recently, [@b22-molce-38-4-297] investigated the functional significance of Ac-Lys in the glycolytic enzymes, aldolase B (ALDOB) and glycerol-3-phosphate dehydrogenase (GPD1). Lysine to glutamine mutation (which mimics constitutive acetylation) ablated enzymatic activity of both enzymes. This finding is intriguing as it presents acetylation as a mechanism to slow down glycolysis. In contrast, in *Salmonella enterica* acetylation of glycolytic enzymes stimulated glycolysis ([@b41-molce-38-4-297]). While differences between these studies likely lie in, among other things, the complexity of the cell type studied, the underlying message is that reversible acetylation of glycolytic enzymes is sufficient to modulate their activity.

Glycogen synthesis
------------------

Glycogen phosphorylase (GP) breaks down glycogen by catalyzing the reaction of glycogen to glucose-1-phosphate ([@b41-molce-38-4-297]). GP is classically thought to be regulated by phosphorylation through the opposing actions of phosphorylase kinase (PK) and protein phosphatase 1 (PP1). While PP1 acetylation sites have been identified ([@b8-molce-38-4-297]; [@b22-molce-38-4-297]), the interplay of phosphorylation and acetylation on the activity of PP1 or its targets is unclear. Recently, GP Lys^470^ and Lys^796^ acetylation were found to negatively regulate glycogen catabolism by promoting PP1-GP interaction through the substrate targeting subunit G~L~, which leads to GP dephosphorylation and inhibition of its activity; however, the KAT responsible was not identified ([@b45-molce-38-4-297]). Additionally, pGSK3β^Ser9^ was reduced in GH3 cells treated with resveratrol, a SIRT1 innibitor, although the mechanism underlying this effect is unknown ([@b24-molce-38-4-297]). Taken together, these results infer that insulin activation leads to acetylation of GP and deacetylation of GSK3β, thereby facilitating glycogen storage.

COORDINATING AND MATCHING CYTOSOLIC PROTEIN ACETYLATION TO GLUCOSE DISPOSAL
===========================================================================

From our discussions above, it is clear that there are many cytosolic proteins that undergo reversible acetylation. Given that acetyl CoA is primarily generated in the mitochondria, a key question is of course, how is acetyl CoA generated in the cytosol to meet requirements for acetylation of proteins found within the cytosol? Citrate generated from the tricarboxylic acid (TCA) cycle is shuttled from the mitochondria into the cytosol when citrate begins to accumulate, where it is cleaved in the cytosol by ATP citrate lyase (ACLY) to produce acetyl CoA ([@b12-molce-38-4-297]). Thus, production of cytosolic acetyl CoA would increase under conditions of increased glucose flux, such as with insulin stimulation. Interestingly, ACLY is directly phosphorylated by Akt, which increases its activity ([@b5-molce-38-4-297]; [@b23-molce-38-4-297]; [@b27-molce-38-4-297]). Moreover, PCAF-mediated acetylation of ACLY at Lys^540/546/554^ stabilizes the protein ([@b21-molce-38-4-297]). Putting these findings together, regulation of ACLY by Akt and acetylation presents an elegant model of matching insulin-stimulated Akt activation and glucose uptake to generation of cytosolic acetyl CoA and subsequent acetylation of cytosolic proteins.

ACETYLATION AS A METABOLIC RHEOSTAT: TYING THE PIECES TOGETHER
==============================================================

Traditionally, insulin signaling to glucose transport has been thought to progress via stepwise phosphorylation. The advent of the 'acetylome', however, provides an exciting additional level of control; such that perturbations in glucose flux are directly linked to changes in the activity (or binding) of insulin signaling proteins and enzymes central to glucose disposal or protein function, through changes in cytosolic acetyl CoA and NAD^+^ levels. By extension this presents a fascinating, but perhaps not surprising model in which acetylation allows for glucose availability to "talk" to proteins in a manner that allows prompt, flexible modulation of enzyme activity and pathway flux. The end result being a transient increase in glucose disposal after insulin stimulation that is in time down-regulated once the cell is sufficiently "full".

While it is easy to ascribe a simple "on" or "off" tag to the effects of acetylation on function, acetylation does not appear binary, but rather a mechanism by which the cell finely tunes its response to insulin. One might think of phosphorylation as the key that turns the engine on or off, whilst acetylation is the accelerator and brake that by extension controls speed (or flux) across a wide spectrum. This is perhaps supported by the fact that many of the proteins in glycolysis are heavily acetylated, thereby providing stepwise control of glucose uptake in conjunction with insulin signaling.

We present a theoretical overview of this in [Fig. 1](#f1-molce-38-4-297){ref-type="fig"}. The translocation of GLUT4 to the plasma membrane is central to insulin-stimulated glucose transport. Under physiological conditions, the number of GLUT4 vesicles recruited to the membrane is a function of the efficiency of insulin signaling. Moreover, maintenance of the interstitial-to-intracellular glucose gradient is essential to maintain glucose transport through GLUT4 after insulin stimulation. In skeletal muscle, this gradient is maintained by conversion of glucose to glucose-6-phosphate (G6P), by hexokinase II (HKII). Once inside the muscle cell, glucose is disposed of oxidatively or non-oxidatively, via glycolysis or glycogen synthesis, respectively, with approximately two-thirds of glucose being shuttled toward glycogen. Thus, if one ascribes that acetylation of glycolytic enzymes results in a general slowing of reaction rates, then there would be an accumulation of intracellular G6P and reduced glucose transport. If concurrently, however, acetylation of glycogen-related enzymes favors glycogen synthesis, then G6P will be incorporated into glycogen, and a picture of flexible coordination of glucose disposal toward glycogen synthesis is revealed. Parallel changes in the cytosolic availability of acetyl CoA and NAD^+^, as a function of glucose flux, would allow for rapid temporal control of the flow of glucose, as well as simultaneous modulation of the acetylation status of insulin signaling proteins. The end result being coordinated control of insulin signaling, with glucose uptake and glucose disposal by acetylation. Certainly, the fact that insulin stimulation leads to activation of ACLY adds credence to this line of thinking.

In this Minireview our goal has been to extrapolate the importance of acetylation to the regulation of insulin-stimulated glucose uptake and glucose metabolism, with a primary focus on skeletal muscle. Our reason for focusing on skeletal muscle is two-fold: skeletal muscle is the primary site for glucose disposal in the post-prandial state, and impairments in this disposal is a key predictor for the development of many metabolic diseases, including type 2 diabetes ([@b11-molce-38-4-297]). Thus, if we can understand "if and how" acetylation affects insulin signaling and glucose metabolism in muscle, then more effective treatment can be developed. Overall, however, there are clearly more questions than answers. One major issue in extrapolating to skeletal muscle is that many of the to-date identified Ac-Lys residues in the insulin signaling pathway (but not glucose metabolism) were not identified in human skeletal muscle ([@b8-molce-38-4-297]; [@b22-molce-38-4-297]). Part of the reason for this could be that the muscle tissue was not insulin-stimulated, which might limit overall coverage. As such, it will be very interesting in future studies to compare the acetylome of basal vs. insulin-stimulated muscle, our hypothesis being that more proteins will be revealed to be acetylated after insulin stimulation. As part of this, determining if different patterns of acetylation exist between insulin sensitive compared to insulin resistant muscle, and whether this is altered by interventions that enhance insulin action, such as caloric restriction or exercise, will be highly insightful. For instance, in rat skeletal muscle, the acetylation of proteins is higher in aged/insulin resistant vs. young/insulin sensitive rats, whilst exercise normalizes acetylation in aged muscle to a level seen in young ([@b19-molce-38-4-297]); whether or not any of these proteins are related to insulin signaling or glucose metabolism is unknown.

Another pressing question is, does acetylation of insulin signaling proteins in skeletal muscle modulate their function? In addition, very little data exists regarding the specific KATs and DACs that regulate Ac-Lys residues of the enzymes and proteins of insulin signaling and glucose metabolism, let alone the acetylome as a whole. Furthermore, the discovery of various other lysine acylations, such as malonylation, succinylation, proprionylation, provide an additional link between nutrient flux and protein function ([@b9-molce-38-4-297]). Studies using pharmacological or gene-based approaches, in parallel with 'omics analysis and measurement of insulin-stimulated glucose uptake will be most helpful in addressing these gaps in knowledge.

In conclusion, in this review we examined the exciting topic of acetylation as an additional regulatory pathway in insulin signaling and glucose metabolism. Clearly 'omics analysis has unlocked the door to the acetylome, and as a result, it is tempting to extrapolate functional outcomes (in our case, insulin action) from changes in protein and enzyme acetylation. Without doubt, however, many questions remain to be answered before the door is fully opened, and we look forward to exciting discoveries in the coming years.
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![Theoretical overview of acetylation in insulin signaling and glucose metabolism. (A) KATs and DACs have been shown to regulate the acetylation patterns of various proteins within the insulin signaling pathway. However, the exact pattern of acetylation and the effect acetylation plays in response to insulin stimulation is not known. (B) Acetylation within glucose metabolism has been shown to regulate glycolytic enzymes and promote glycogen synthesis. However, the dynamics of acetylation patterns within these pathways, and the KATs and DACs that regulate them, following insulin stimulation, are not known. (C) Insulin stimulation may activate ACLY within the cytosol that produces acetyl CoA, from Citrate, required for subsequent acetylation of target proteins.](molce-38-4-297f1){#f1-molce-38-4-297}

###### 

Acetylation sites in the insulin signaling pathway

  Protein                   Lys-Ac Sites              Ref                                  
  ------------------------- ------------------------- ------------------------ ----------- -------------------------------------------------------------------
  **Insulin Signaling**                                                                    
                                                                                           
  IR                        \--                       \--                      \--         \--
  IRS1                      K52, K61                  \--                      K315        [@b1-molce-38-4-297], [@b11-molce-38-4-297]
  IRS2                      \--                       K118, K289, K292, K412   \--         [@b2-molce-38-4-297], [@b4-molce-38-4-297], [@b6-molce-38-4-297]
  p85α                      K530                      \--                      K633        [@b1-molce-38-4-297]
  p55α                      K106, K114                \--                      \--         [@b1-molce-38-4-297]
  p55γ                      K308                                                           [@b2-molce-38-4-297]
  p110β                     K159, K173                \--                      \--         [@b1-molce-38-4-297]
  p110γ                     K1000                     \--                      \--         [@b1-molce-38-4-297]
  PDK1                      K304                      K307, K495, K534         K307        [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b7-molce-38-4-297]
  mTORC2                    K25, K228, K629           K229, K628               K25, K228   [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b4-molce-38-4-297]
  Rictor                    (9)K, K213, K582, K1312   K1311                    \--         [@b1-molce-38-4-297], [@b8-molce-38-4-297]
  Akt1                      K14, K20, K420, K426      \--                      \--         [@b1-molce-38-4-297], [@b7-molce-38-4-297]
  Akt2                      K378                      \--                      \--         [@b1-molce-38-4-297], [@b5-molce-38-4-297]
  AS160                     K477                      \--                      \--         [@b2-molce-38-4-297], [@b5-molce-38-4-297]
  GLUT4                     \--                       \--                      \--         \--
  GSK3β                     \--                       \--                      \--         \--
  ACLY                      (16)K                     (12)K                    (17)K       [@b1-molce-38-4-297]. [@b9-molce-38-4-297]
                                                                                           
  **Negative Regulators**                                                                  
                                                                                           
  PTEN                      (7)K, K125, K128          K125, K128               K266        [@b1-molce-38-4-297], [@b4-molce-38-4-297], [@b10-molce-38-4-297]
  PTP1B                     K131, K141                \--                      \--         [@b1-molce-38-4-297]
  SKIP                      \--                       \--                      \--         \--
  SHIP2                     K272                      K902                     \--         [@b1-molce-38-4-297], [@b2-molce-38-4-297]
  TRB3                      \--                       \--                      \--         \--

IR, Insulin receptor; IRS1/2, Insulin receptor substrate-1/2; p85, p50, p55, p110, PI3K subunits; PDK1,3-Phosphoinositide dependent protein kianse 1, mTORC2, Mammalian target of rapamycin complex 2; Rictor, Raptor independent companion of mTOR; Akt1, v-akt murine thymom viral oncogene homolog 1; Akt2, v-akt murine thymom viral oncogene homolog 2; AS160, Akt substrate of 160 kDa; Glut4, Insulin-responsive glucose transporter type 4; GSK3β, Glycogen synthase kinase 3 beta; ACLY, ATP-Citrate Lyase; PTEN, Phosphatase and tenisin homolog; SKIP, Inositol polyphosphate-5-phosphatase K; SHIP2, Inositol polyphosphate phosphatase-like 1; TRBP3, Tribbles Pseudokinase 3; \--, Not available. Note: Numbers inside paranthese preceeding, K (Lys), denote the number of Lys-Ac sites identified in each species. (1), [www.phosphosite.org](www.phosphosite.org); (2), [@b22-molce-38-4-297]; (3), [@b8-molce-38-4-297]; (4), [@b41-molce-38-4-297]; (5), Chen et al 2012; (6), [@b44-molce-38-4-297]; (7), [@b36-molce-38-4-297]; (8), [@b13-molce-38-4-297]; (9), [@b21-molce-38-4-297]; (10), [@b25-molce-38-4-297]; (11), [@b46-molce-38-4-297].

###### 

Acetylation and glucose metabolism

  Protein          Lys-Ac Sites   Ref                                   
  ---------------- -------------- ------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------------------
  **Glycolysis**                                                        
                                                                        
  HK               (3)K           (4)K                (18)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297]
  G6P              (12)K          (8)K                (20)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297], [@b5-molce-38-4-297]
  PFK              (6)K           \--                 (13)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297], [@b5-molce-38-4-297]
  ALDO             (16)K          (7)K                (14)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297], [@b5-molce-38-4-297]
  TPI              (12)K          (12)K               (14)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297], [@b5-molce-38-4-297]
  GAPDH            (18)K          (14)K               (15)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297], [@b5-molce-38-4-297]
  PGK              (29)K          (19)K               (22)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297], [@b5-molce-38-4-297]
  PGlyM            (3)K           (1)K                (8)K              [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297], [@b5-molce-38-4-297]
  ENO              (2)K           (4)K                (17)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297], [@b5-molce-38-4-297]
  PK               (23)K          (3)K                (12)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297], [@b5-molce-38-4-297]
                                                                        
  **Glycogen**                                                          
                                                                        
  GCK              K296           K296                \--               [@b1-molce-38-4-297], [@b2-molce-38-4-297]
  PGluM            (3)K           (18)K               (14)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297]
  UGP              (5)K           (13)K               (12)K             [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b4-molce-38-4-297]
  GS               (3)K           \--                 (2)K              [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b4-molce-38-4-297]
  GP               (4)K           (13)K, K470, K796   \--               [@b1-molce-38-4-297], [@b2-molce-38-4-297], [@b3-molce-38-4-297], [@b4-molce-38-4-297], [@b5-molce-38-4-297], [@b6-molce-38-4-297]
  GLYG             \--            \--                 K27, K209, K229   [@b1-molce-38-4-297], [@b2-molce-38-4-297]

HK, Hexokinase; G6P, Glucose-6-phosphate isomerase; PFK, Phosphofructose-kinase; ALDO, Aldolase; TPI, Triosephosphate isomerase; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; PGK, phosphoglycerate kinase; PGlyM, phosphoglycerate mutase; ENO, Enolase; PK, Pyruvate Kianse; GCK, glucokinase; GS, glycogen synthase; PGluM, phosphoglucose mutase; UGP, UTP-glucose-1-phosphate uridyltransferase; GS, Glycogen synthase; GP, Glycogen phosphorylase; GLYG, Glycogenin; H, Human; M, Mouse; R, Rat; \--, Not available. Note: Numbers inside paranthese preceeding, K (Lys), denote the number of Lys-Ac sites identified in each species. (1) [www.phosphosite.org](www.phosphosite.org); (2), [@b22-molce-38-4-297]. (3) [@b8-molce-38-4-297]. (4) Guan et al 2010. (5) Chen et al 2012; (6), [@b45-molce-38-4-297].
